Notice about cookies

Close

This website uses a limited number of cookies to improve your browsing experience. For further information (including how to withdraw consent), please refer to our Cookie Policy. By clicking Accept below or continuing to use this website (including closing this message), you confirm that you have read and consent to our use of cookies as detailed in our Cookie Policy.

Accept

UCB's Global Corporate Website
Welcome to UCB in the United States

Categories

Archives

Jul

10

Helen Tarleton Recognized as a Working for Cures Employee Champion

Read More Share:linkedin| twitter| email

Jun

24

FINTEPLA® (fenfluramine) Results Examining its Impact in Managing Generalized Tonic-Clonic Seizures in Developmental and Epileptic Encephalopathies Published in Epilepsia

Read More Share:linkedin| twitter| email

Jun

20

UCB Launches Dravet Syndrome Sound of Profound Moments: Family Video Project

Read More Share:linkedin| twitter| email

Jun

13

UCB at EULAR 2024: Advancing Science for Rheumatic Conditions with High Unmet Needs

Read More Share:linkedin| twitter| email

Jun

13

New CIMZIA® data for women living with chronic rheumatic diseases throughout pregnancy, and for people living with RA and high rheumatoid factor levels

Read More Share:linkedin| twitter| email

Jun

12

UCB to share first presentations of BIMZELX® (bimekizumab-bkzx) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024

Read More Share:linkedin| twitter| email

Jun

10

Nicole Watson: Mom, Caregiver, and Best Friend, Shares How Her Daughter Emma, Diagnosed with Dravet Syndrome, Embraces Each Day with Love

Read More Share:linkedin| twitter| email

May

31

Go Behind The Mystery of Myasthenia Gravis On Myasthenia Gravis Awareness Month

Read More Share:linkedin| twitter| email

May

31

Empowering the Hidradenitis Suppurativa Community: UCB's Triple Approach

Read More Share:linkedin| twitter| email

May

23

UCB Announces Publication in The Lancet of Phase 3 BIMZELX® (bimekizumab-bkzx) Trials in Moderate-to-Severe Hidradenitis Suppurativa

Read More Share:linkedin| twitter| email

© 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
USPR-CORP-0115-00003(2)